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Abstract
S-adenosylhomocysteine hydrolase (AHCY) deficiency is a rare autosomal recessive disor-
der in methionine metabolism caused by mutations in the AHCY gene. Main characteristics
are psychomotor delay including delayed myelination and myopathy (hypotonia, absent ten-
don reflexes etc.) from birth, mostly associated with hypermethioninaemia, elevated serum
creatine kinase levels and increased genome wide DNA methylation. The prime function of
AHCY is to hydrolyse and efficiently remove S-adenosylhomocysteine, the by-product of
transmethylation reactions and one of the most potent methyltransferase inhibitors. In this
study, we set out to more specifically characterize DNA methylation changes in blood sam-
ples from patients with AHCY deficiency. Global DNA methylation was increased in two of
three analysed patients. In addition, we analysed the DNAmethylation levels at differentially
methylated regions (DMRs) of six imprinted genes (MEST, SNRPN, LIT1, H19,GTL2 and
PEG3) as well as Alu and LINE1 repetitive elements in seven patients. Three patients
showed a hypermethylation in up to five imprinted gene DMRs. Abnormal methylation in Alu
and LINE1 repetitive elements was not observed. We conclude that DNA hypermethylation
seems to be a frequent but not a constant feature associated with AHCY deficiency that
affects different genomic regions to different degrees. Thus AHCY deficiency may represent
an ideal model disease for studying the molecular origins and biological consequences of
DNA hypermethylation due to impaired cellular methylation status.
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Introduction
AHCY (S-adenosylhomocysteine hydrolase; EC 3.3.1.1) removes SAH (S-adenosyl-L-homo-
cysteine) formed in each S-adenosylmethionine (SAM)-dependent methyltransferase reaction
by catalysing its hydrolysis to adenosine and homocysteine [1, 2]. In eukaryotes, SAM is the
main source of methyl groups used by methyltransferases to modify DNA, RNA, proteins and
cellular metabolites [3].
A complete loss of AHCY leads to embryonic lethality in mice [4]. Compound heterozygous
mutations of the human AHCY gene resulting in a reduced activity of AHCY have been
reported in eight patients [5–11]. Patients displayed characteristic biochemical abnormalities
with marked elevations of plasma SAH, SAM, methionine and creatine kinase accompanied by
a significant decrease in the SAM/SAH ratio. Clinical characteristics include myopathy, hypo-
tonia, psychomotor delay, abnormalities of liver function tests and delayed myelination [5–11].
Dietary methionine restriction and supplementation with creatine and phosphatidylcholine
can lead to improved myelination and psychomotor development [5, 6]. However, this dietary
therapy of patients did not eliminate or decrease elevated global leukocyte DNAmethylation, a
further important feature of AHCY deficiency that was measured by incorporation of [3H]
dCTP into DNA of patients compared to that of control individuals [5, 6].
DNA methylation is linked to transcriptional repression via recruitment of methylcytosine-
binding proteins and chromatin-modifying factors to cis-regulatory elements. It is crucial for
normal development and differentiation, with particular importance in processes like genomic
imprinting, X-chromosome inactivation, silencing of transposons and inactivation of tumor
suppressor genes [12–14].
Genomic imprinting leads to a parent-of-origin-specific gene expression due to allele-spe-
cific DNA methylation. Imprinted genes are most often found in clusters and regulated by
CpG (cytosine phosphate guanosine)-rich differentially methylated regions (DMRs). Methyla-
tion at these DMRs is more static, as it is established during the development of germ cells and
maintained during the life cycle of the developing organism with only minor modifications
[15]. Many imprinted genes have essential regulatory functions in fetal and placental growth
and development, somatic differentiation, as well as neurological and behavioral processes.
Imprinting defects can cause severe syndromes with physical and mental retardation, e.g. Pra-
der-Willi syndrome and Angelman syndrome [15]. Since imprinted genes robustly maintain
their DNAmethylation in healthy somatic tissues, they can serve as ideal indicators for the epi-
genetic stability of a cell or an individual [16].
LINE1 and Alu repetitive elements are derived from retrotransposons and encompass 17%
and 10% of the human genomic sequence, respectively [17]. The 6000–7000 bp long full length
LINE1 element is capable of autonomous retrotransposition, but the majority of LINE1 ele-
ments represent 50-truncated, internally rearranged or mutated sequences that are retrotran-
sposition-defective [18]. The ~ 300 bp long non-autonomous Alu elements belong to the
family of short interspersed nuclear elements (SINEs). They are CpG-rich and account for
one-third of the total CpG sites in the human genome [19]. In somatic tissues, LINE1 and Alu
elements usually display high methylation levels that inhibit retrotransposition activity [20].
Thus, LINE1 and Alu methylation levels are also regarded as excellent surrogate indicators of
genome wide alterations in DNAmethylation.
The aim of this study was to more thoroughly determine leukocyte DNA methylation
changes in patients with AHCY deficiency by quantifying global DNA methylation and DNA
methylation at DMRs of six imprinted genes (MEST, SNRPN, LIT1,H19, GTL2 and PEG3) as
well as Alu and LINE1 repetitive elements.
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Results
Global DNA methylation analysis
Wemeasured global DNAmethylation levels in patients A, B and F (Table 1) using the Methyl-
Flash Methylated DNA Quantification Kit (Epigentek). Patients A and B showed methylation
levels that were 5.6 ± 3.0 times (patient A, p = 0,001) and 6.5 ± 3.1 times (patient B, p = 0,011)
as high as those of the controls (n = 3) (Fig 1). In contrast, patient F displayed a methylation
level similar to that of controls (1.3 ± 0.7 times, Fig 1). To confirm that the three control sam-
ples analysed in parallel to the three patient samples are representative for the normal popula-
tion, 10 additional age- and sex-matched controls (5 females and 5 males) were analysed in a
subsequent experiment together with the DNA of patient B. This experiment also detected a
markedly elevated methylation level of patient B compared to the 10 control samples. These
control samples displayed methylation levels very similar to those of the three controls of the
first experiment and no significant sex difference in methylation levels (S1 Fig). Due to the lim-
ited amounts of available DNA, global DNAmethylation analysis could not be performed for
patients C, D, E and G.
Table 1. List of analysed patients with AHCY deficiency.
Patient Gender Age at blood
withdrawal for DNA
extraction
Age at begin of
dietary
treatment
AHCY mutations Elevation of
plasma SAH
levels
Elevation of
plasma SAM
levels
SAM/SAH
ratio
References
A m ~ 1 year > 1 year c.428A>G; p.Y143C
(pat)c.336G>A; p.
W112X (mat)
150x 30x 0.59 [5,6]
B m After birth < 0.5 years c.428A>G; p.Y143C
(pat) c.336G>A; p.
W112X (mat)
5x 1,6x 1.13 [6]
C m After birth < 0.5 years c.428A>G; p.Y143C
(pat) c.336G>A; p.
W112X (mat)
6,5x 1,8x 0.28 [10]
D f ~ 1 month < 0.5 years c.428A>G; p.Y143C
(pat) c.336G>A; p.
W112X (mat)
unknown unknown unknown unpublished
E m ~ 26 years 1–6 years c.428A>G; p.Y143C
(pat) c.266C>T; p.
A89V (de novo)
28xa 20xa 0.71 [7]
Fb f ~ 14 days 76 days c.145C>T; p.R49C
(pat) c.257A>G; p.
D86G (mat)
81 23 0.28 [8, 11]
G f > 1,5 years 22 months c.982T>G; p.Y328D
(pat) c.428A>G; p.
Y143C (mat)
200x 50x 0.62 [21]
Patients A-D are siblings. Treatment by dietary methionine restriction and supplementation with creatine and phosphatidylcholine lead to normalisation of
SAH levels [5, 6]. Dietary treatment for patient E was stopped after 5 years and included restriction of methionine to 20 mg/kg/day and of protein to 1.0–
1.4 g/kg/day. Patient F was dietary treated with 50% methionine-free formula (Hominex1) and 50% Pregestimil1, providing 27 mg/kg per day of
methionine, and supplements of creatine (3 g/day) and phosphatidylcholine (1,200 mg/day) [8]. Dietary therapy of Patient G consisted of methionine
restriction ( 35 mg/kg/day; i.e.  2 g total dietary protein per kg/day) and dietary supplements of creatine (300 mg/kg/day) and phosphatidylcholine (200
mg/kg/day) [21]. SAM/SAH ratios were directly taken from the references or calculated with the absolute concentrations given in the references. m = male,
f = female, pat = paternal, mat = maternal
a values obtained at age of 26 years
b died at age of 4 months
doi:10.1371/journal.pone.0151261.t001
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Methylation analysis of imprinted gene DMRs as well as LINE1 and Alu
repetitive elements using bisulfite pyrosequencing
Using bisulfite pyrosequencing, we quantified the methylation levels of six imprinted gene
DMRs (MEST, SNRPN, LIT1,H19, GTL2 and PEG3) as well as LINE1 and Alu repetitive ele-
ments (Table 2 and Fig 2) in all seven patients (Table 1). Methylation was regarded as moder-
ately or highly abnormal (hyper- or hypomethylated) if the measured methylation values were
at least 10% or 20% higher or lower than the mean methylation values measured in the control
individuals. For all analysed regions, the threshold of 10% represented more than twice the
standard deviation (SD) of methylation values determined in control individuals.
We detected abnormal methylation values in three of the seven analysed patients. All cases
of abnormal methylation values were associated with increased methylation, i.e. we only
observed abnormal hypermethylation and no abnormal hypomethylation in the three patients.
Patient A was the only patient that displayed highly abnormal hypermethylation that affected
MEST and H19. In addition, patient A showed moderately abnormal hypermethylation for
LIT1 and PEG3. Patients D and F exhibited moderately abnormal hypermethylation forMEST,
PEG3 andH19. Patient F further displayed moderately abnormal hypermethylation for LIT1
and SNRPN. We found no abnormal methylation values for GTL2 as well as the LINE1 and
Alu elements.
Fig 1. Genome widemethylation levels in three patients with AHCY deficiency and controls. Patients A and B showed genome wide methylation levels
more than five times as high as those of controls, patient F displayed a genome wide methylation level similar to that of controls. The bars display the ratio of
methylation levels of the three patients normalised to that of three control samples in three independent measurements. Variation between the three control
samples was included via error propagation.
doi:10.1371/journal.pone.0151261.g001
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In addition, we did not find a correlation between the elevation of SAH levels (Table 1) as a
reference for severity of AHCY deficiency and DNAmethylation changes. Patient G exhibited
the highest elevation of SAH levels (200-fold), but no abnormalities in DNAmethylation.
To analyse if AHCY deficiency only stochastically affects the methylation of single CpG
sites in the analysed regions, we also compared the methylation values of all CpG sites included
Fig 2. Three patients with AHCY deficiency show abnormal hypermethylation in some imprinted gene DMRs. Bisulfite pyrosequencing results of six
imprinted gene DMRs as well as LINE1 and Alu repetitive elements in seven patients and controls. Only patients A, D and F showed abnormal
hypermethylation of some, but not all imprinted gene DMRs. No methylation errors were observed for the repetitive elements. The bars show the mean
methylation values, the error bars display the standard deviation of two to four independent measurements. Moderately abnormal methylation values are
indicated by a single asterisk (*), highly abnormal methylation values by a double asterisk (**).
doi:10.1371/journal.pone.0151261.g002
Table 2. Methylation levels determined by bisulfite pyrosequencing analysis.
Patient MEST
(5 CpGs)
LIT1
(2 CpGs)
PEG3
(3 CpGs)
H19
(3 CpGs)
SNRPN
(6 CpGs)
GTL2
(5 CpGs)
LINE1
(3 CpGs)
ALU
(3 CpGs)
A 78,64 ± 5,86 65,76 ± 2,29 69,11 ± 6,13 93,33 ± 4,99 52,46 ± 5,01 64,47 ± 0,56 76,33 ± 2,79 25,45 ± 1,77
B 49,31 ± 1,95 50,81 ± 1,42 54,95 ± 0,85 55,24 ± 2,55 42,03 ± 4,73 58,68 ± 2,56 82,84 ± 5,05 25,05 ± 1,54
C 45,16 ± 3,04 46,29 ± 3,67 47,61 ± 5,36 50,69 ± 1,67 39,16 ± 3,76 56,74 ± 2,03 80,41 ± 11,13 25,75 ± 1,49
D 63,24 ± 5,79 49,60 ± 5,04 71,25 ± 1,32 67,00 ± 0,24 46,43 ± 5,07 58,57 ± 2,22 71,98 ± 1,32 26,34 ± 1,27
E 43,62 ± 3,80 43,66 ± 3,28 50,57 ± 0,24 52,53 ± 2,61 37,88 ± 6,89 52,24 ± 2,61 70,44 ± 1,50 26,34 ± 1,81
F 65,08 ± 2,46 61,87 ± 2,12 65,29 ± 0,42 71,12 ± 3,01 66,08 ± 3,97 63,36 ± 1,36 75,60 ± 1,77 27,98 ± 0,53
G 47,48 ± 0,84 53,81 ± 0,24 52,29 ± 1,11 50,38 ± 3,36 44,32 ± 3,46 58,11 ± 0,98 78,08 ± 1,51 29,49 ± 0,03
Controls (n = 8) 47,58 ± 1,99 50,49 ± 3,72 51,09 ± 3,82 55,85 ± 4,25 44,37 ± 1,87 61,59 ± 3,57 77,80 ± 2,27 27,36 ± 1,00
Methylation levels [%] of six imprinted gene DMRs and two repetitive elements were measured. The number of analysed CpG sites is given in brackets
below each analysed region. Samples with methylation levels differing by more than 10% to those of controls are highlighted in bold, samples with
methylation levels differing by more than 20% are highlighted in bold and underlined.
doi:10.1371/journal.pone.0151261.t002
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in the same pyrosequencing assay. Methylation values of CpG sites included in the same assay
did not differ by more than 10% in any analysed gene and sample (exemplarily shown forMEST
in Fig 3). These results indicate that hypermethylation of imprinted genes induced by AHCY
deficiency generally affected all and not only single CpG sites included in the analyzed DMRs.
Verification of pyrosequencing data with high resolution melting analysis
To confirm the results of the bisulfite pyrosequencing analysis, we additionally used high reso-
lution melting (HRM) analysis to quantify the methylation ofMEST, SNRPN andH19 in
patients A, B and F as well as three controls. HRM analysis quantifies overall methylation status
of the whole PCR amplicon (i.e. mean methylation of all CpG sites of the PCR product), but
does not allow to measure a methylation value for a single CpG site. We detected mean methyl-
ation values ± SD (standard deviation) for the three analysed imprinted genes that did not dif-
fer by more than 10% compared to the mean methylation values determined by bisulfite
pyrosequencing (Table 3 and Fig 4). Thus, we were able to confirm the moderately and highly
abnormal hypermethylation found forMEST and H19, respectively, in patients A and F as well
as the moderately abnormal hypermethylation established for SNRPN in patient F.
Fig 3. Methylation values of single CpG sites analysed in theMEST bisulfite pyrosequencing assay. DNAmethylation [%] determined by
pyrosequencing at five consecutive CpG sites in theMESTDMR in the seven patients and controls. The CpG sites within the pyrosequencing assay are
ordered according to their indicated position in the genome (Ensembl version 76).
doi:10.1371/journal.pone.0151261.g003
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Discussion
In the present study, we have shown abnormally increased global DNA methylation in two
(patients A and B) of three tested patients with AHCY deficiency and abnormal hypermethyla-
tion of imprinted gene DMRs in three (patients A, D and F) of seven tested patients with
AHCY deficiency. For the two patients A and B displaying abnormal hypermethylation at the
global level these observations confirm the increased global DNAmethylation already reported
in a previous study [5, 6]. Our finding of DNA hypermethylation in overall four (patients A
and B with global hypermethylation and patients A, D and F with imprinted gene hypermethy-
lation) but not in the remaining three (patients C, E and G) analysed patients with AHCY defi-
ciency suggests that abnormally increased methylation is a frequent but not a constant feature
associated with AHCY deficiency.
Global DNA methylation changes have also been reported for other monogenic syndromes.
To our knowledge, however, patients affected by these syndromes never exhibited DNA
Fig 4. HRM analysis confirms pyrosequencing data of patients A, B and F. High resolution melting (HRM) analysis gives the mean methylation status of
the complete PCR amplicons of three imprinted gene DMRs. PCR primers for theMEST, SNRPN andH19DMRs used for pyrosequencing also worked for
HRM analysis to confirm pyrosequencing results. DNA of patients A, B and F were analysed together with controls. The mean values ± standard deviation did
not differ by more than 10%methylation between pyrosequencing and HRM analysis for any of the analysed DMRs. The bars show the mean methylation
values, the error bars the standard deviation of two independent measurements.
doi:10.1371/journal.pone.0151261.g004
Table 3. Methylation levels determined by high resolutionmelting analysis.
Patient MEST (23 CpGs) H19 (18 CpGs) SNRPN (21 CpGs)
A 81,76 ± 1,85 86,84 ±4,31 50,07 ± 2,07
B 34,62 ± 5,51 48,14 ±5,38 30,95 ± 11,96
F 71,12 ± 3,85 84,78 ±6,05 53,07 ± 2,07
Controls 46,24 ± 3,49 43,74 ±3,68 33,26 ± 5,21
Methylation levels [%] of three imprinted gene DMRs were measured. The number of analysed CpG sites is given in brackets below each analysed
region.
doi:10.1371/journal.pone.0151261.t003
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hypermethylation, but DNA hypomethylation or a mixture of DNA hypomethylation and
hypermethylation signatures. One prominent example is the rare autosomal recessive Immu-
nodeficiency, Centromeric Instability, Facial Anomalies (ICF) syndrome which, in about 60%
of cases, is caused by mutations in the gene encoding the de novo DNAmethyltransferase
DNMT3B [22, 23]. Patients with ICF syndrome have a constitutional methylation defect with
severe hypomethylation mainly affecting heterochromatic sequences [24]. Other examples are
the Hutchinson-Gilford Progeria (HGP) and Werner syndrome (WS), two premature aging
disorders characterized by common natural aging already in childhood and attributed to muta-
tions in the lamin A (LMNA) and the Werner syndrome RecQ helicase like (WRN) genes [25–
27]. Array-based genome wide DNAmethylation profiling of HGP andWS patients with either
causative mutations in the LMNA andWRN genes or unknown etiology revealed aberrant
DNAmethylation and global DNA methylation differences with DNA hypomethylation and
hypermethylation signatures between LMNAmutant,WRNmutant and non-mutant patients
that also affect genes involved in aging processes [28]. Interestingly, a connection between the
molecular pathogenesis of HGP and modulations of the folate–homocysteine–methionine axis
has been already suggested but up to now not experimentally proven [29].
Our results must be further discussed in the light of the current knowledge on the existence
of an imprinted gene network (IGN) that exerts a critical role in regulating embryonic growth
[30]. TheH19 gene was suggested to represent an important trans regulator in the fine-tuning
of this IGN in the mouse embryo by controlling the expression of several other imprinted
genes including Igf2, Slc38a4, Dcn, Dlk1, Peg1/Mest, Gtl2, Cdkn1c and Igf2r [31]. Further stud-
ies in the mouse showed that a complex between theH19 long noncoding RNA and the
methyl-CpG–binding domain protein 1 MBD1 is needed for the control of five of these genes
(Igf2, Slc38a4, Dcn, Dlk1, and Peg1/Mest) with MBD1 binding directly to the DMRs of three of
them (Igf2, Slc38a4 and Peg1/Mest) [32]. Interestingly, both H19 andMEST displayed abnor-
mally increased methylation levels in the three AHCY patients for whom hypermethylation of
several imprinted genes was detected out of the seven patients analyzed. In addition, H19 and
MEST even were the only two imprinted genes for which highly abnormal hypermethylation
was detected in one of these three patients (patient A). Thus, it is tempting to speculate that
some patients with AHCY suffer from a general deregulation of the IGN due to abnormal
hypermethylation of its master regulator H19. As a limitation of this hypothesis, it has, how-
ever, also to be considered that GTL2 as another IGN member regulated byH19 is not affected
by abnormal hypermethylation at all.
Only one previous study that analysed mice with diet-induced hyperhomocysteinemia
reported an association between increased SAH levels and abnormal gene-specific hyper-
methylation affecting the Fads2 gene (encoding Δ(6)-desaturase) [33]. Other human and
mouse studies analysed healthy young women,Mthfr (methylenetetrahydrofolate reductase)
knockout mice and Cbs (cystathionine β-synthase) heterozygous knockout and wild-type mice
fed a control or methyl-deficient diet, respectively. These studies exclusively correlated the ele-
vation of SAH with decreased DNA methylation [34–36]. Further reports on Sprague-Dawley
rats and ApoE knockout mice with induced hyperhomocysteinemia and 2 to 6-fold elevated
SAH levels specifically associated the DNA hypomethylation with repetitive B1 elements, the
murine equivalent of human Alu repetitive elements [37, 38].
In AHCY deficient patients, however, LINE1 and Alu elements did not show abnormal
DNAmethylation. This is not completely unexpected since particularly LINE1 methylation
has already been reported to exhibit little variability in blood [39] and thus has been questioned
to be sensitive enough for detecting subtle changes in DNAmethylation. In addition, bisulfite
pyrosequencing of LINE1 and ALU elements uses consensus sequences to determine methyla-
tion levels of only 3 to 4 CpG sites among half a million of LINE‐1 and*1.4 million Alu
Abnormal Hypermethylation of Imprinted Genes in AHCY Deficiency
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elements [40]. Thus, the number of assessed elements is unclear and may even vary between
individuals making the assays not entirely representative of global DNA methylation [41]. Fur-
ther limitations of these assays with regard to the representation of global DNAmethylation
could arise from the fact that methylation of repetitive elements may be regulated by different
mechanisms than methylation of the other parts of the genome [42].
In all studies mentioned above, DNA hypomethylation was attributed to the action of SAH
as a potent product inhibitor of SAM-dependent methyltransferases [43]. In the light of these
data, our finding of DNA hypermethylation in AHCY deficient patients seems to be rather
unexpected. However, the mentioned studies also showed a decrease of SAM levels, whereas
AHCY deficiency increases SAM levels and therefore the amount of substrate for methyltrans-
ferases (MTs). Furthermore, AHCY deficiency leads to a much more pronounced, more than
100-fold increase of SAH [44] compared to the moderate SAH increase associated with DNA
hypomethylation in the above mentioned studies. Thus, a reversal of the effect on DNA meth-
ylation may be induced by the transition from moderately elevated to highly elevated SAH lev-
els. A similar reversal was already reported for the effect of elevated homocysteine on CCNA1
(cyclin A) transcription: Elevation of homocysteine in clinically relevant concentrations lead to
inhibited vascular endothelial cell growth via hypomethylation and transcriptional inhibition
of the CCNA1 gene that was accompanied by accumulation of SAH [45]. In contrast, elevation
of homocysteine in supraphysiological concentrations promoted proliferation and transcrip-
tion of CCNA1 in vascular smooth muscle cells [46]. Hence, it can be speculated that the mas-
sive and simultaneous accumulation of SAH and SAM typically seen in AHCY deficiency may
reduce or abolish product inhibition of SAM-dependent DNA methyltransferases (DNMTs).
In this context, it has further to be considered that DNMT1 was already reported to be less
sensitive to SAH than other SAM-dependent non-DNAMTs [47]. In mammals, more than 200
SAM-dependent MTs have been identified [48–50]. Thus, it can be hypothesised that the non-
DNAMTs may remain inhibited at higher SAH concentrations present in AHCY deficiency and
leave the excess SAM to the DNMTs which then increase DNAmethylation in patients. Barić
et al. already suggested the myelin basic protein-arginine N-methyltransferase PRMT7 as one
non-DNAMT that may be involved in the etiology of AHCY deficiency [51]. This enzyme cata-
lyzes the arginine methylation of myelin basic protein, an important component of myelination,
which is known to be delayed in AHCY deficiency [51]. 100-fold elevation of SAH was shown to
reduce the activity of this MT by about 90% [52]. By comparison, hyperhomocysteinemia associ-
ated with increased SAH levels reduced the activity of DNMT1 only by 30% [45].
In the light of our data, three further critical questions have to be asked: (i) Why did only
four of the seven patients with AHCY deficiency exhibit abnormally increased methylation val-
ues? (ii) Why were there two patients that either displayed abnormal global hypermethylation
but not increased imprinted gene methylation (patient B) or increased imprinted gene methyl-
ation but not abnormal global hypermethylation (patient F)? (iii) Why did we not observe a
correlation between the elevation of SAH levels as a reference for severity of AHCY deficiency
and the occurrence of DNAmethylation changes? Based on the hypothesis already mentioned
above, it is possible that only the patients that exceeded a critical threshold of elevated SAH lev-
els at the embryonic stage underwent fetal programming during early to mid-gestation leading
to DNA hypermethylation to different degrees, i.e. not necessarily detectable at the global level,
and at different genomic locations. As an example of fetal programming, supplementation of
viable yellow agouti (Avy) mice with dietary methyl donors and cofactors involved in SAM-sub-
strated methylation such as folate, methionine, choline, and vitamin B12 throughout gestation
and lactation was already shown to increase methylation at the Avy metastable epiallele of the
agouti coat colour locus in the offspring thereby changing their phenotype from yellow obese
to pseudoagouti lean [53]. The window of susceptibility for altering the epigenetic state of the
Abnormal Hypermethylation of Imprinted Genes in AHCY Deficiency
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Avy allele and the phenotype was determined to be from early to mid-gestation [54, 55]. It is
important to note that mouse embryos harbouring a complete deletion of the Ahcy gene die
two to three days after Ahcy is first expressed at the peri-implantation stage which lies in the
middle of the above mentioned window of susceptibility [4]. A further mouse metastable epial-
lele with findings similar to those reported for the Avy allele is the axin fused (AxinFu) locus
[56]. Putative human metastable epialleles have been also already described [57] and may be
promising candidates for more detailed methylation analysis in AHCY deficient patients. A
global DNAmethylation analysis of the patients which, owing to lack of sufficient genomic
DNA, were up to now only studied for imprinted gene methylation, would be necessary to fur-
ther corroborate the hypothesis of fetal programming dependent on SAH levels present around
implantation. In addition, the fact that only some patients with AHCY deficiency display DNA
hypermethylation and these patients are even not all affected at the global or gene-specific level
may reflect the involvement of the AHCY protein in a multitude of cellular pathways and com-
plex protein interaction networks including more than 200 SAM-dependent MTs and thereby
adjusting the metabolic machinery of the cell and individual. This is further mirrored by the
large variety of clinical disease presentations such as potential lethality in early life [11] and
association with hepatocellular carcinoma [58] as well as by the highly diverse successful treat-
ment strategies discussed below.
The standard therapeutic treatment of AHCY deficiency consists of a methionine-restrict-
ing diet and supplementation with creatine and phosphatidylcholine [5, 6]. This can lead to an
improved development and normalisation of SAH levels [6]. Interestingly, rats that displayed a
reduced SAM/SAH ratio and global DNA hypomethylation due to a 9-week long methyl-defi-
cient diet reacquired normal global methylation values by subsequent refeeding with a normal
diet. Normal global methylation levels, however, could not be restored when the rats received
the methyl-deficient diet longer than 9 weeks [59]. In the light of these findings, it would be
interesting to study the methylation levels of the patients again after months or even years of
treatment and verify if a normalisation of methylation levels can be achieved. Barić et al.
(2005) already analysed global DNA methylation of leukocyte DNA in patients A and B after
31 and 10 months of dietary treatment, respectively. Although methylation levels did not nor-
malise, the authors noted a possible trend towards a reduction of global DNA methylation [6].
Another recently reported innovative therapeutic approach included the transplantation of
a liver segment from a healthy, unrelated living donor to patient G and lead to a normalisation
of blood methionine and SAM levels as well as an improvement of development with a 4-fold
accelerated head growth and promising gains in gross motor, language, and social skills [21].
Should this therapeutic approach become available for other AHCY-deficient patients with
DNAmethylation changes, analysis before and after treatment could also give further insights
into the possible plasticity of the methylation defects.
Conclusions
To our knowledge, AHCY deficiency is the first monogenic disease with DNA hypermethylation
that occurs as a frequent but not a constant feature and affects different genomic regions to differ-
ent degrees. The massive and simultaneous accumulation of SAH and SAM typically associated
with AHCY deficiency may reduce or abolish product inhibition of SAM-dependent DNAmethyl-
transferases but not SAM-dependent non-DNAmethyltransferases and thus increase DNAmeth-
ylation in patients. These abnormal DNAmethylation reactions may have occurred only in
patients that exceeded a critical threshold of elevated SAH levels at the embryonic stage and thus
underwent fetal programming during early to mid-gestation. We consider AHCY deficiency to be
an ideal model disease for studying the molecular origins and biological consequences of DNA
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hypermethylation due to impaired cellular methylation status. A deeper insight into this disease
may contribute to a better understanding of the epigenome´s plasticity and its susceptibility to crit-
ical changes in one-carbon metabolites. Specifically, further studies are warranted that monitor
long-term changes in DNAmethylation but possibly also histone methylation at the gene-specific
and genome wide level during dietary treatment or after liver transplantation therapy.
Materials and Methods
Patients and controls
Patients analysed in this study are listed in Table 1. This study was performed on DNA
extracted from peripheral blood samples. Due to insufficient amount of available material from
some patients, not all samples could be analysed with all methods. The entire study was
approved by the ethical commission of the Medical Faculty Zagreb. The informed consent for
using the patients´ samples for research to their benefit has been obtained directly from the
proband or biological parent in the case of minors and has been signed in the presence of the
responsible physician. The ethical commission of the Medical Faculty Zagreb has evaluated the
informed consent for patients A-F and has issued an approval form to the responsible scientist
(OV) for usage of patient cell lines for research purposes only. The Institutional Review Board
of Lancaster General Hospital approved the study of patient G and the informed consent of
patient G's parents. Age- and sex-matched controls as well as adult controls were included in
the study and did not show any significant methylation differences with the methods used.
Genome wide methylation analysis
The genome wide methylation analysis of patients A, B and F as well as three control samples
was performed in three technical replicates using the MethylFlash Methylated DNA Quantifi-
cation Kit (Epigentek) according to the manufacturer’s instructions with 200 ng of genomic
DNA for each sample. Global DNA methylation levels of patient samples were normalised to
the average of the control group in three independent measurements. Variation between con-
trols was included via error propagation. Statistical analysis was performed using Kolmogo-
rov–Smirnov test followed by independent samples t-test. In a subsequent experiment, 10
further age- and sex-matched control samples (5 female and 5 male) were analysed in the same
way together with the DNA of patient B to confirm that the three control samples of the first
experiment are representative for the normal population.
DNA isolation, bisulfite conversion, PCR and pyrosequencing
Human genomic DNA was isolated with the DNeasy blood and tissue kit (Qiagen) according
to the manufacturer’s instructions and quantified using a NanoDrop 2000 spectrophotometer.
450 ng DNA per sample were used for bisulfite conversion with the Epitect 96 bisulfite kit (Qia-
gen). PCR and pyrosequencing with primers for the DMRs of SNRPN, LIT, PEG3, H19,MEST
and GTL2 as well as LINE1 and Alu elements were performed as described elsewhere [60]. Pyr-
osequencing was performed on a PyroMark Q96 ID (Qiagen) with PyroMark Gold Q96
reagents (Qiagen). Data were analysed using the PyroMark CpG Software 1.0.11 (Qiagen).
High resolution melting analysis
HRM analyses were performed using a CFX96 Real-Time PCR Detection System (BioRad).
Each PCR was performed in a final volume of 15 μl, containing 7.5 μl Precision Melt Supermix
(BioRad), 400 nM of each primer, and 20 ng of bisulfite-converted DNA (theoretical concen-
tration presuming no loss of DNA during bisulfite modification). PCR amplification was
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performed with one step of 95°C for 2 min; 45 cycles of 95°C for 10 s, 56/58°C for 30 s and
72°C for 15 s; followed by an HRM step of 95°C for 30 s, 60°C for 1 min, 65°C for 10 s and con-
tinuous acquisition to 90°C at one acquisition per 0.2°C. Primers for SNRPN,H19 andMEST
were the same as for bisulfite pyrosequencing PCR reactions. Buccal swab DNA from a healthy
donor was used to generate fully methylated and unmethylated bisulfite-converted DNA stan-
dards. 50 ng of DNA was used for whole genome amplification using the REPLI-g midi kit
(Qiagen) to generate the unmethylated standard DNA. The reaction was performed according
to the manufacturer's instructions. An aliquot of 100 μg was in vitro methylated with 400 U
SssI methylase and 640 μM SAM (NEB) according to the manufacturer's instructions. After 4
hours at 37°C, additional SAM and 50 units of M.SssI methylase were added and incubated
overnight at 37°C to ensure complete methylation. Both methylated and unmethylated DNA
samples were purified by phenol-chloroform extraction followed by ethanol precipitation and
suspended in DNase-free water. They were mixed to obtain methylation levels of 0%, 25%,
50%, 75% and 100% and were included in duplicates in each assay. Commercially available
bisulfite-converted DNA standards (Qiagen) were analysed together with the in house-made
DNA standards and confirmed their methylation levels. HRM data were analysed using Bio-
Rad Precision Melt Analysis Software (BioRad) with output plots produced as normalised
melting curves. Normalised relative fluorescent units (RFUs) were exported to Prism 6 (Graph-
pad). Area under the curve (AUC) was calculated and the quadratic regression was used to
interpolate the unknown samples to the standards (R2 was> 0.98). Due to the variability of the
dynamic range between the standards, this method is suitable for methylation analysis of
imprinted genes but not repetitive elements.
Supporting Information
S1 Fig. Genome wide methylation levels of 10 further age- and sex-matched control samples
analysed together with patient B. The bars display the genome wide 5-methyl-cytosine meth-
ylation levels [%] obtained in one measurement of patient B and the mean 5-methyl-cytosine
methylation and standard deviation [%] detected in one measurement of 5 female and 5 male
control samples, respectively.
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